14 November 2024
14 November 2024
Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease treatment.
Syndax shared topline data from its Phase II AUGMENT-101 trial, but the results failed to convince investors.
The company plans to discontinue the study after the combination therapy failed to meet the primary endpoint in the Phase III trial.
Under the agreement, BioNTech will pay Biotheus shareholders an $800m upfront consideration.
The approval is based on the results from the Phase III MOMENTUM trial.
Alexander aims to enhance Valo Health's mission to accelerate drug discovery and development.
The alliance is designed to expedite the discovery of vital insights for cancer treatment.
The approval is based on the positive outcome of the multicentre ADHERE study.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
